An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer
Authors:
- Srivani KonduriSKSrivani Konduri
- Niranjan AwasthiNANiranjan Awasthi
- Danielle CafassoDCDanielle Cafasso
- Margaret A. SchwarzMSMargaret A. Schwarz
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Pancreatic cancer: From molecular signature to target therapyCritical Reviews in Oncology/Hematology, 2008
- New directions in the management of advanced pancreatic cancer: a reviewAnti-Cancer Drugs, 2008
- Gemcitabine Plus Celecoxib in Patients With Advanced or Metastatic Pancreatic AdenocarcinomaAmerican Journal of Clinical Oncology, 2008
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic CancerJournal of Clinical Oncology, 2006
- Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III TrialJournal of Clinical Oncology, 2005
- Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response RateJournal of Clinical Oncology, 2004
- Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297Journal of Clinical Oncology, 2002
- A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancerBritish Journal of Cancer, 2002
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000